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Abstract: Dystonia pathophysiology has been partly linked to downregulation and dysfunction
of dopamine D2 receptors in striatum. We aimed to investigate the possible morpho-structural
correlates of D2 receptor downregulation in the striatum of a DYT1 Tor1a mouse model. Adult
control Tor1a+/+ and mutant Tor1a+/−mice were used. The brains were perfused and free-floating
sections of basal ganglia were incubated with polyclonal anti-D2 antibody, followed by secondary
immune-fluorescent antibody. Confocal microscopy was used to detect immune-fluorescent signals.
The same primary antibody was used to evaluate D2 receptor expression by western blot. The D2
receptor immune-fluorescence appeared circumscribed in small disks (~0.3–0.5 µm diameter), likely
representing D2 synapse aggregates, densely distributed in the striatum of Tor1a+/+ mice. In the
Tor1a+/− mice the D2 aggregates were significantly smaller (µm2 2.4 ± SE 0.16, compared to
µm2 6.73 ± SE 3.41 in Tor1a+/+) and sparse, with ~30% less number per microscopic field, value
correspondent to the amount of reduced D2 expression in western blotting analysis. In DYT1 mutant
mice the sparse and small D2 synapses in the striatum may be insufficient to “gate” the amount of
presynaptic dopamine release diffusing in peri-synaptic space, and this consequently may result in a
timing and spatially larger nonselective sphere of influence of dopamine action.
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1. Introduction
Dystonia is a disorder of movement characterized by disturbed agonist-antagonist muscle
activation [1], with particular difficulty switching between sequential muscles involved in a complex
task, either voluntary or involuntary [2]. Symptomatic dystonia can be observed in various neurological
disorders, including cerebrovascular diseases, Parkinson’s disease, and Wilson’s disease [3]. Unlike
symptomatic dystonia, no pathologic correlate is still known for many dystonic disorders categorized
as idiopathic dystonia, and further divided into generalized, focal, and segmental dystonia [4].
In the past, various dystonic forms were often interpreted in psychological or psychiatric terms
until the late 19th century [3,5], when the descriptions of familial forms of generalized primary torsion
dystonia suggested that it is an organic disease [6,7]. The identification of genetic mutations in some
families in the late 20th century established an organic framework for idiopathic dystonia (see 3).
The most common and severe form of genetic dystonia is caused by a 3 bp deletion (GAG) in
the coding region of the TOR1A (DYT1) gene, which results in a defective protein called torsinA [8].
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Although hereditary, DYT1 dystonia has a childhood or adolescent clinical onset [4]. However,
significant neurodegeneration could not be documented at the histological level in any brain areas
of patients with DYT1 dystonia [9,10], suggesting that dystonia pathophysiology is determined
by functional rather than structural abnormalities. Several neurophysiological and neuroimaging
studies, as well as new genetic insights, have been so far performed in DYT1 dystonia, contributing
to define functional abnormalities in the basal ganglia [11–15]. Clinical neuroimaging studies have
revealed decreased caudate-putamen dopamine D2 receptor availability in DYT1 patients compared
to controls [16,17]. Moreover, reduced striatal D2 receptor binding and protein level have also
been reported in several different DYT1 experimental models [18–20]. Aside from D2 receptor
downregulation, multiple lines of evidence demonstrated reduced coupling between the D2 receptor
and its cognate G proteins, as well as severely altered D2 receptor electrophysiological plasticity
in the striatum but not in the substantia nigra [18,21–25]. Comparative studies on the functions of
D1, D2, an A2A receptors, as well as of different neurotransmitters (dopamine, GABA, glutamate,
acetylcholine) have been performed by Pisani et al. in mouse models of dystonia, demonstrating
a selective downregulation and dysfunction of D2 receptors [18,21,23]. In addition, a recent paper
has clarified the mechanisms of D2 receptor downregulation in the striatum, mediated by increased
lysosomal degradation, associated in turn with lower levels of striatal RGS9-2 and spinophiling,
opening a new approach to the therapy [26]. Therefore, it is generally assumed that abnormal striatal
synaptic plasticity, and D2 receptor-dependent striatal outflow abnormalities have a leading role in
determining basal ganglia pathophysiology in DYT1 dystonia [27,28]. The developmental profile of
the aberrant D2 receptor function has been studied in DYT1 mutant mice, recording in cholinergic
neurons an abnormal excitatory response to the D2 receptor agonist quinpirole since postnatal day 14,
which persisted at three and nine months in hMT mice [22].
We aimed to investigate possible morpho-structural correlates of D2 receptor downregulation in
striatum of an adult DYT1 knock-out mouse model.
2. Results
We first quantified the levels of D2 receptors on proteins extracted from the striatum. In line with
a previous study [26] western blotting analysis revealed a significant ~ 30% reduction (p < 0.05) of D2
receptor levels in the striatum of mutant Tor1a+/− compared to control Tor1a+/+ mice (Figure 1).
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Figure 1. (a) Comparative immunoblots of D2 receptors from the striatum of control Tor1a+/+, and
mutant Tor1a+/−mice. β-actin content was detected as internal reference standard. (b) Densitometric
analysis of relative optical density (OD) on D2 receptors immune-stained bands. Results were expressed
as the mean ± SEM of the values obtained for each separate hemisphere from four mice per group.
* p < 0.05.
Light microscopy immune-histochemistry demonstrated an intense D2 receptor brown peroxidase
reaction product reactivity in the striatum (Figure 2A). In control Tor1a+/+, the striatum displayed D2
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positive neuronal perikarya, peripherally outlined by an intense reaction product, and surrounded
by a diffuse lighter neuropil staining. These data document a large distribution of D2 receptors on
neuronal bodies, and neuropil of striatal neurons. In Tor1a+/− the D2 peroxidase reaction product
appeared less intense around neuronal bodies, as well as in the neuropil of the striatum (Figure 2B),
confirming the western blot analysis. However, the diffuse brown reaction product detectable by the
D2 light microscopy immune-histochemistry can give just a rough idea of the D2 densitometric changes
around neuronal bodies and neuropil, but does not allow a precise definition of the morpho-structural
characteristics of the D2 receptor aggregates in control and mutant mice.
Figure 2. Representative microphotographs of D2 receptor immune-histochemistry in control Tor1a+/+
(A), and mutant Tor1a+/− knock-out (B) mice. The brown reaction product is clustered around neuronal
bodies and diffused in the neuropil. Scale bar in B = 100 µm.
Immune-fluorescence images were acquired with a LSM700 Zeiss confocal laser scanning
microscope (Zeiss, Germany): 5× and 20× objectives were used to define areas of interest in the
dorsolateral striatum; distribution of D2 receptors was first acquired using 63× oil immersion lens
(1.4 numerical aperture), and thereafter with an additional digital zoom factor (1×–1.5×–2×). Images of
D2 immune-fluorescence acquired with a 63× oil immersion lens at first look appeared as a shiny galaxy
in a starkly sky, with clusters of extremely small grains covering diffusely the neuronal compartments
of the striatum, without apparent difference between perikarya and neuropil, whereas grains were
rare and almost absent on the cell nuclei and in striatal axonal bundles (Figure 3). The density of D2
positive fluorescent grains was clearly different between the striatum of Tor1a+/+ and Tor1a+/−mice.
In Tor1a+/+ the D2 positive grain were contiguous and even superimposed each other, whereas in the
striatum of Tor1a+/−mice the D2 positive grains were close but separated from each other (Figure 3).
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Figure 3. Representative immune-fluorescence microphotographs of confocal laser scanning microscopy
(63×), double-labeled for D2 receptors and for nuclei in the striatum of control Tor1a+/+ (A), and of
mutant Tor1a+/− knock-out (B) mice. D2 receptor immune-labeling is visualized in red-Cy3 fluorescence,
while nuclei are visualized by DAPI fluorescence in blue. Bar in B = 10 µm.
A better understanding of D2 receptors subcellular distribution came out in images acquired using
a 63× oil immersion lens (1.4 numerical aperture) with an additional digital zoom factor (1×–1.5×–2×).
The immune-fluorescent signal appeared extremely specific without background staining so that the
D2 receptor localization appeared circumscribed in very small disks, roundish or elliptical in shape,
of size variable with a diameter between ~0.3–0.5 µm in the striatum of Tor1a+/+ mice (Figure 4A).
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Figure 4. Representative immune-fluorescence microphotographs of high magnification (63× plus
zoom factor 1×–1.5×–2×) confocal laser scanning microscopy, double-labeled for D2 receptors and for
nuclei in the striatum of control Tor1a+/+ (A), and of mutant Tor1a+/− knock-out (B) mice. D2 receptor
immune-labeling is visualized in red-Cy3 fluorescence, while nuclei are visualized by DAPI fluorescence
in blue. Bar in B = 2 µm.
In the striatum of Tor1a+/− mice, the D2 positive disks appeared sparse (Figure 4B), and the
number and size of D2 positive disks and their total area per microscopic field was significantly lower
in the striatum of Tor1a+/− than in corresponding areas of Tor1a+/+ mice (Figure 5A–C). Moreover, the
mean distance between D2 positive disks was <1 µm for most of the disks in the striatum of Tor1a+/+
but > 2 µm for most of the disks in corresponding areas of Tor1a+/− mice (as can be easily seen in
Figure 4).
Int. J. Mol. Sci. 2020, 21, 1073 5 of 12
Figure 5. Comparative densitometric analysis of the D2 immune-fluorescence in the striatum of control
Tor1a+/+ and mutant Tor1a+/− knock-out transgenic mice. (A) Total D2 positive area per microscopic
field through 63× oil immersion objective. df = 1, F = 31.202; p < 0.0001. (B) Number of D2 positive disks
per microscopic field through 63× oil immersion objective (1.4 numerical aperture) with an additional
digital zoom factor (1×–1.5×–2×). df = 1, F = 13.406; p < 0.001. (C) Size of D2 disk (µm2) through 63×
oil immersion objective (1.4 numerical aperture) with an additional digital zoom factor (1×–1.5×–2×).
df = 1, F = 6.543; p < 0.04. Results were expressed as the mean + SE of average values detected within
the randomly selected microscopic areas of the dorsolateral caudate-putamen of both hemispheres
from four mice in each group. Comparison among groups was performed with the ANOVA one-way.
However, quantitative analysis of the relative immune-fluorescence intensity per single D2 positive
disk in the striatum was slightly less intense in Tor1a+/− than in Tor1a+/+ mice (Figure 6, Table 1),
suggesting that the density of D2 receptors in large and small aggregates is substantially similar in
control and mutant animals.
Figure 6. Table 1—Comparative fluorescence intensity of D2 receptor spots evaluated by Java image
processing and ImageJ in microphotographs from confocal laser scanning microscopy. D2 positive spots
were randomly selected and marked in red in control Tor1a+/+ (A), and mutant Tor1a+/− knock-out (B)
mice. Bar in B = 2 µm. Table 1—Results were expressed as the mean + SE of the area and the average
grey values (0–255) within the selected spots of the dorsolateral caudate-putamen of both hemispheres
from three mice in each group. Marked decrease of the area (see analysis in Figure 5), but not of the grey
level in D2 positive spots was observed in mutant Tor1a+/− knock-out mice, compared with controls.
Table 1. Control Mutant.
Spots Area µm2 Grey level Area µm2 Grey Level
Mean 6.73 252.00 2.4 216.18
± SE 3.41 0.30 0.16 13.63
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3. Discussion
The main finding of our work is that the reduced expression of D2 receptors in the Tor1a+/−striatum
is associated with marked reduction in the number and size, but not in fluorescence intensity of
the D2 positive residual aggregates. These results have however, some limitations in providing a
morpho-structural correlate of the downregulation of D2 receptors in dystonia.
In our study, high-resolution confocal microscopy can give well-defined immune-fluorescent
images of every D2 receptors’ aggregate in the microscopic field, but without configuring at the same
time the mosaic of the surrounding cell structures, unlike electron microscopy immunocytochemistry.
Indeed, immune-fluorescent D2 receptors appear arranged in homogeneous roundish shapes, variable
in size with a diameter between ~0.3–0.5 µm, likely approaching dimensions of dopaminergic synapses
on small dendritic spines (with shaft diameter ~0.04–1 µm and length ~0.1–2 µm) of striatal medium
spiny neurons [29]. The D2 receptor positive disks likely represent the subcellular structures formed
by D2 molecular aggregates, but we can just hypothesize the subcellular sites where the D2 aggregates
are inserted in Tor1a+/+ and in Tor1a+/−mice.
Instead, at the electron microscopy level, in the striatum the D2 receptors were extensively
localized to 38% of dendrites and 48% of spines of medium spiny neurons, and quite frequently on axon
terminals [30]. Moreover, synapses formed by D2 immune-reactive terminals were not always easy to
be identified in the striatum due to a lack of pronounced pre- or postsynaptic densities, suggesting
a significant D2 extra-synaptic localization [30]. Indeed, in the striatum 60%–70% of dopaminergic
axon terminals, supposed to be dopamine release sites, do not make synaptic junctional complex [31].
On the other hand, while photomicrographs obtained by transmission electron microscopy can allow
detailed morphological characteristics of synapses, they can just give a rough estimate of synaptic
sizes, shapes [32], and of spatial distribution frequency, due to the high magnification and limited
electron microscopic fields.
By confocal microscopy in our study, we can obtain a definite spatial arrangement of the D2 signals
with an estimate of sizes and shapes of the D2 receptor aggregates, and of their distribution density
through a relatively large microscopic field. D2 receptor aggregates have generally a disk-shape and a
size in the range of dimension of dendritic spines, and so D2 receptor aggregates have morphological
similarity with synapses which can be categorized as macular synapses among the three main types of
synaptic junctions (macular, perforated, and horseshoe-shaped synapses) [33]. Therefore, we would
try to approximately interpret the reduction in number and size of the D2 aggregates in the striatum of
Tor1a+/−mice as a global reduction of D2 synapses, but without differentiating between the synaptic
and extra-synaptic sites. Reduction in synapses’ number and size is a well-known mechanism reducing
efficiency of neuronal connectivity. However, the residual D2 synapses in Tor1a+/− mice display
immune-fluorescence intensity and macular shape similar to those seen in Tor1a+/+ mice, suggesting
that the synaptic arrangement and intensity of D2 receptors can be preserved in mutant animals.
A reduced topographic density of D2 synapses would be particularly relevant for dopamine
transmission in the striatum of Tor1a+/−mice. Indeed, dopaminergic transmission is predominantly
characterized as nonsynaptic or peri-synaptic volume transmission, since most dopaminergic receptors
are extra-synaptic, i.e., rather distant from directly opposing dopaminergic terminal varicosities [29].
Once released by tyrosine hydroxylase (TH) positive terminals, dopamine is normally not limited in a
synaptic cleft but diffuses far away from release sites, traveling through extracellular spaces usually
along an effective radius of 7 µm in three dimensions, until dopamine molecules bind to synaptic and
extra-synaptic D1 and D2 receptors or are cleared up by presynaptic dopamine transporters [29,34,35].
In Tor1a+/−mice, sparse D2 synapses in the striatum have to face a normal density of dopamine
axon terminals, since the TH-positive axonal networks in mutant animals do not show morphologically
obvious abnormalities in the striatum [36]. Moreover, there was no significant difference in striatal
dopamine content between mutant and control mice, while its metabolite homovanillic acid (HVA)
was higher suggesting that dopamine turnover was significantly increased in the mutant mice [36,37],
according to evidence for increased dopamine turnover observed in the striatum of DYT1 patients [38].
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Therefore, in DYT1 mutant mice the dopamine peri-synaptic landscape appears specifically changed,
since D2 synapses are sparse in the striatum, but the sites of presynaptic dopamine release appear to
be preserved [36,37]. In this scenario, dopamine molecules diffusing away from release sites can have
a minor probability of binding in contiguous D2 synapses [39], so that they may have a large radius of
diffusion, until they are bound by D1 and D2 receptors and/or are cleared up by presynaptic dopamine
transporters. On the basis of the peri-synaptic dopamine volume efflux model, we hypothesize that
in DYT1 mutant mice the sparse D2 synapses may be insufficient to “gate” a relatively abundant
dopamine efflux, and this consequently may result in a timing and spatially larger nonselective sphere
of influence of dopamine action.
The model of sparse D2 synapses can help interpret some aspects of DYT1 physiopathology in
basal ganglia. At first glance, it seems inexplicable that the baseline and amphetamine-stimulated
dopamine release detected by microdialysis is lower in mutant DYT1 mice compared with controls,
while at the same time the caudate-putamen tissue dopamine levels were normal [36]. We can interpret
the reduced dopamine release in mutant animals to be compensatory to D2 sparse synapses. Moreover,
sparse D2 synapses can explain why DYT1 dystonia individuals do not respond to medications that
alter dopamine transmission [36], since D2 synapses are sparse, there would be already a relative
ceiling action of endogenous dopamine quantal release from dopamine preserved synaptic terminals.
Finally, sparse D2 synapses can clearly differentiate the morpho-functional correlates of basal ganglia
physiopathology in dystonia and Parkinson’s disease, the one characterized as post-synaptic pathology
with D2 sparse synapses insufficient to gate dopamine efflux from preserved dopaminergic terminals,
the other as a presynaptic pathology with loss of striatal dopamine release terminals but conserved D1
and D2 receptors in experimental parkinsonian monkey [40]. Moreover, in tissues from parkinsonian
patients who died without receiving L-dopa in the last weeks of life, the binding of a radioactive ligand
to Dl or D2 was elevated 20%–60% above the neurological control tissue [41]. Accordingly, dopamine
receptor agonists are useful medications even regarded as first choice to delay the starting of L-dopa
therapy in Parkinson’s disease [42], but ineffective in DYT1 dystonia [36].
Although the sparse D2 synapses may have a relevant role in DYT1 physio-pathology, it cannot
be inferred that the observed D2 alteration is primary and specific, since the D2 receptors distribution
in the striatum was not compared with other receptors in our study. In a previous work, we have
demonstrated that in DYT1 mice carrying human mutant torsinA (hMT), the enkephalinergic neurons
express a higher cellular content of the neuropeptide enkephalin and of PDE10A, a key enzyme in the
catabolism of the second messenger nucleotides [43]. Therefore, we can infer that the downregulation
of D2 receptors, predominantly expressed by the medium spiny enkephalinergic neurons, seems to be
a primary process not secondary to reduced cellular capacity of protein synthesis in DYT1 dystonia.
However, it is not known whether the downregulation of the D2 receptors is selective and specific
to the physiopathology of dystonia, or it is part of a larger process involving altered expressions of
other receptor types, and in particular of the adenosine 2A (A2A) receptor subtype. It is worth noting
that in the enkephalin positive striatal medium spiny neurons there is evidence for colocalization
of the D2 receptors with the A2A receptors, which together form intramembrane cell complexes
called heteromers, functionally interacting in a reciprocal antagonistic manner [44]. Likely, sparse D2
synapses may also result in an impaired D2/A2A interaction in DYT1 dystonia.
Further studies should investigate the synaptic and extra-synaptic distribution of the sparse
D2 aggregates and of D2/A2A heteromers, evaluating their relationship with dopamine volume
transmission in the physiopathology of basal ganglia microcircuits in DYT1 mutant mice. Moreover,
clarifying the developmental morpho-structural characteristics of the D2 receptor aggregates and of
D2/A2A etheromers in the DYT1 mouse model would be helpful to develop preventative treatment
before clinical manifestation of disease.
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4. Materials and Methods
4.1. Animals and Methods
C57BL/6 Tor1a+/− knock-out transgenic mice, that mimic the loss of function of the DYT1
dystonia TOR1A mutation [45], were bred at the Santa Lucia Foundation Animal Facility; mice were
sacrificed at 5–6-months-old. DNA was isolated and amplified from 1- to 2-mm tail fragments with
the Extract-N-Amp Tissue polymerase chain reaction (PCR) kit (XNAT2 kit; Sigma-Aldrich, Milan,
Italy, and genotyping performed as reported by Bonsi et al. [26]. All the efforts were made to minimize
the number of animals utilized and their suffering. Treatment and handling of mice were carried
out in compliance with both the EC and Italian guidelines (2010/63EU, D.lgs. 26/2014; 86/609/EEC;
D.Lvo 116/1992), according to experimental protocols approved by the Animal Ethics Committee
of the University of Rome “Tor Vergata” (D.M. 153/2001-A and 43/2002-A), and by the Santa Lucia
Foundation Animal Care and Use Committee (D.M. 9/2006-A), and authorized by the Italian Ministry
of Health (authorization # 223/2017-PR).
For biochemical studies, the animals (n = 5 Tor1a+/+, n = 5 Tor1a+/− knock-out) were killed by
cervical dislocation, and their brains were removed rapidly and placed on an ice-cold plate. Thick
brain sections were cut with an Oxford vibratome, and the caudate-putamen was dissected out rapidly
from both hemispheres, and promptly frozen in liquid nitrogen and stored at –80 ◦C [46].
For morphological studies, the animals were deeply anesthetized with tiletamine/zolazepam
(80 mg/Kg) and xylazine (10 mg/Kg), and perfused trans-cardially with 1% heparin in a 50 mL 0.1 M
sodium phosphate buffer, and with 250 mL 4% paraformaldehyde in a 0.1 M sodium phosphate buffer
(pH 7.4). The brains were removed immediately and post-fixed in the same fixative solution overnight
at 4 ◦C. Coronal brain sections 40-µm-thick were cut with an Oxford vibratome across the entire
rostro-caudal extent of the basal ganglia, and collected and stored at 4 ◦C in a 0.1 M phosphate buffer
that contained 0.02% sodium azide, as previously described [43].
4.2. Quantitative Analysis of D2 Protein
The quantitative analysis of D2 receptor expressions in the striatum was assessed by western
blotting. Tissues were lysated in 10 mM Tris–HCl pH 8, 150 mM NaCl, 1% v/v Triton X-100, 0.1%
w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 1 mM EDTA, 5 mM β-mercaptoethanol,
1 mM PMSF, and protease inhibitor cocktail (Sigma-Aldrich). Thirty µg of proteins were loaded on a
9% SDS polyacrylamide gel and subjected to electrophoresis under reducing condition. The proteins
were then transferred to a nitrocellulose membrane (Bio-Rad). The blots were incubated overnight
at 4 ◦C with a rabbit polyclonal anti-D2 receptor antibody (1:1000, AB5084P; Millipore); or mouse
anti-β-actin (1:10,000; Sigma-Aldrich) as a reference standard. Immune-reactive bands were revealed
by horseradish peroxidase-conjugated secondary antibodies (1:10,000, Jackson Immunoresearch),
incubated in a lumi-light-enhanced chemiluminescence substrate (Bio-Rad) and exposed to chemidoc
(Bio-Rad). Densitometric analysis of scanned blots was performed using the NIH ImageJ version l.29
program (NIH, Bethesda, MD, USA).
4.3. Immune-Histochemistry
Coronal brain sections including the sensorimotor cerebral cortex, and the caudate-putamen
were processed for identification of D2 positive receptors. Briefly, free floating sections were washed
three times with Tris-buffered saline, pH 7.4, and endogenous peroxidase activity was inactivated
by incubation for 5 min in Tris-buffered saline that contained 2% H2O2. Sections were rinsed with
a Tris-buffered saline that contained 0.1% Triton X-100, and incubated with 2% normal goat serum,
followed by overnight incubation at 4 ◦C with the primary polyclonal antibody (1:500) rabbit anti-D2
receptors (AB5084P, Millipore). The primary antibody was detected using a biotinylated secondary
antibody (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA), and an avidin horseradish
peroxidase/diaminobenzidine/H2O2 chromogen system (Sigma-Aldrich, Milan, Italy). The specificity
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of the immunocytochemical reaction was confirmed by the absence of staining after omission of the
primary antibody. After the diaminobenzidine reaction, the sections were rinsed with Tris-buffered
saline and mounted on gelatine-coated slides, dehydrated, and cover-slipped with Permount for light
microscopy examination. The sections were observed and photographed with a light microscope
(Olympus BX51, Tokyo, Japan) equipped with an automatic micro camera (LeicaDC 300 F, Q550 IW
Soft, Wetzlar, Germany).
4.4. Immune-Fluorescence Techniques and Confocal Microscopy
To evaluate the D2 receptor immune-fluorescence in striatal neurons, slices processing and confocal
image acquisition were performed according to Bonsi et al. [26]. Mice were deeply anesthetized and
perfused with cold 4% paraformaldehyde in a 0.12 M phosphate buffer (pH 7.4). The brain was
post-fixed for at least 3 h at 4 ◦C and equilibrated with 30% sucrose overnight. Coronal brain sections
(40 µm thick) were cut with a freezing microtome. Slices were dehydrated with serial alcohol dilutions
(50%–70%–50%) and then incubated 1 h at room temperature in a 10% donkey serum solution in PBS
0.25%-Triton X-100 (PBS-Tx). The primary rabbit anti-D2 antibody (AB5084P, Millipore) was utilized
(1:500, three days at 4 ◦C). The following secondary antibodies were used (1:200, room temperature, 2 h):
Alexa 488 and Alexa 647 (Invitrogen), and cyanine 3 (cy3)-conjugated secondary antibodies (Jackson
ImmunoResearch, Cambridge House, UK). Cell nuclei were detected with a blue-fluorescent DNA
stain by 4′,6-diamidino-2-phenylindole (DAPI) (D9542, Sigma-Aldrich, Milan, Italy). After washout,
slices were mounted on plus polarized glass slides with a Vectashield mounting medium (Super Frost
Plus; Thermo Fisher Scientific) and coverslipped.
Images were acquired with a LSM800 Zeiss confocal laser scanning microscope (Zeiss, Germany),
with a 5×, 20× objective, or 63× oil immersion lens (1.4 numerical aperture) with an additional
digital zoom factor (1×–1.5×–2×) under no saturation conditions. Single-section images (1024 × 1024)
or z-stack projections in the z-dimension (z-spacing, 1 µm) were collected. Z-stack images were
acquired to analyze the whole neuronal soma, which spans multiple confocal planes. The confocal
pinhole was kept at 1, the gain and the offset were adjusted to prevent saturation of the brightest
signal and sequential scanning for each channel was performed. The confocal settings, including
laser power, photomultiplier gain, and offset, were kept constant for each marker. For quantitative
immune-fluorescence analysis, images were collected from at least 3–4 slices processed simultaneously
from each striatum (n ≥ 4 mice/genotype) and exported for analysis with the ImageJ software (NIH).
Software background subtraction was utilized to reduce noise.
The intensity of D2 fluorescence per D2 positive spots was evaluated by Java image processing
and ImageJ. Briefly, the D2 positive spots in immune-fluorescence microphotographs were randomly
selected using a drawing selection circle closely around, and the red color image of D2 fluorescence
intensity was analyzed by converting each pixel in greyscale (0–255). The minimum and maximum
grey values within the selection were detected, and the mean grey value (the sum of the grey values of
all the pixels in the selection area divided by the number of pixels) per spot was calculated.
4.5. Statistical Analysis
Data analysis was performed using the Statistical Package for the Social Sciences Windows, version
15.0 (SPSS). Descriptive statistics consisted of the mean ± SE for parameters with Gaussian distributions
(after confirmation with histograms and the Kolgomorov–Smirnov test). The homogeneity of the
variance was evaluated by Levene’s test. Comparison among groups was performed with the ANOVA
one-way. P-value < 0.05 was considered statistically significant.
5. Conclusions
The reduced expression of D2 receptors in the striatum of Tor1a+/− dystonic mice is associated
with marked reduction in number and size of the D2 positive synapses. D2 sparse and small synapses
may be insufficient to “gate” a relatively abundant dopamine release diffusing extrasynaptically
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through the interstitial space among striatal neurons. This may result in a longer duration and
larger sphere of influence of dopamine transmission, making its action non-selective in striatal
micro-circuitries. Our study suggests a relevant role for dopamine volume transmission in DYT1
dystonia physiopathology.
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